Maria Corinna Palanca Wessels

Maria Corinna Palanca Wessels

University of Washington - Seattle / United States
Medical and Health Sciences / Hematology
AD Scientific Index ID: 1684789
person_outline Maria Corinna Palanca Wessels's MOST POPULAR ARTICLES
1-) Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial The Lancet 390 (10094), 555-566, 2017
2-) Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a … The Lancet Oncology 16 (6), 704-715, 2015
3-) Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Blood, The Journal of the American Society of Hematology 125 (9), 1394-1402, 2015
4-) Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Leukemia 29 (7), 1578-1586, 2015
5-) Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypesM Pfeifer, B Zheng, T Erdmann, H Koeppen, R McCord, M Grau, A Staiger, ...Leukemia 29 (7), 1578-1586, 20151692015